| C57 | Factors associated with never testing for HIV among transgender women in São Paulo, Brazil | E-poster | Prevention in transgender populations |
| C59 | Working with Christian faith-based organisations to prevent HIV/AIDS and unwanted pregnancy in Delta State of Nigeria | E-poster | Assessing impact of structural interventions and social protection |
| C4 | Prevention-effective adherence trajectories among transgender women indicated for PrEP in the United States: findings from the LITE American Cohort | E-poster | Epidemiology of HIV in transgender people |
| C14 | Estimating the impact of HIV on cervical cancer elimination: a comparative modelling analysis in South Africa | E-poster | Modelling the HIV epidemic |
| C27 | Effectiveness and medication adherence of daily and event-driven pre-exposure prophylaxis regimens among Chinese men who have sex with men: a real-world CROPrEP study | E-poster | PrEP |
| C27 | Long-acting capsid inhibitor effective as PrEP against vaginal SHIV transmission in macaques | E-poster | PrEP |
| C27 | Long-acting injectable PrEP in women: laboratory analysis of HIV infections in HPTN 084 | E-poster | PrEP |
| C28 | Prioritizing the evaluation of HIV prevention interventions in pregnancy: Interim results from a randomized, open-label safety trial of dapivirine vaginal ring and oral tenofovir disoproxil fumarate/emtricitabine use in late pregnancy | E-poster | Microbicides (including vaginal and rectal microbicides) |
| C31 | HIV-1 Env markers of prevention efficacy in HVTN 704/HPTN 085, the Antibody-Mediated Prevention (AMP) trial of broadly neutralizing antibody (bnAb) VRC01 in the Americas and Europe: genotypic sieve analysis | E-poster | Broadly neutralizing antibodies |
| C34 | Integrating viral hepatitis and PrEP services through KP-led clinics in Vietnam: an opportunity to achieve dual elimination of HIV and viral hepatitis by 2030 | E-poster | Prevention for co-morbidities (e.g., TB, viral hepatitis) |